{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T19:37:51Z","timestamp":1775936271920,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0010425","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000}}],"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RTG1949"],"award-info":[{"award-number":["RTG1949"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TR1208\/1-1"],"award-info":[{"award-number":["TR1208\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TR1208\/2-1"],"award-info":[{"award-number":["TR1208\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Else Kr\u00f6ner-Promotionskolleg ELAN"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Neutralizing antibodies (nAbs) prevent the entry of viruses into permissive cells. Since nAbs represent correlates of protection against the Rabies lyssavirus, the presence of sufficient nAbs indicates effective vaccination. Accordingly, Rabies lyssavirus-specific nAb titers need to be determined in routine diagnostics to identify individuals being at risk of Rabies lyssavirus infections due to insufficient immunity. The current gold standard for the quantification of Rabies lyssavirus-specific nAbs is the <jats:italic>rapid fluorescent focus inhibition test<\/jats:italic> (RFFIT). However, RFFITs are expensive and labor-intensive since multiple microplate wells must be evaluated one-by-one by trained personnel through microscopic inspection, which limits the number of samples that can be processed. To overcome this disadvantage, we established a novel assay for Rabies lyssavirus-specific nAbs relying on an in-cell-ELISA (icELISA)-based neutralization test (icNT). The icNT differs from the RFFIT in the readout phase, and can be automatically quantified in minutes using broadly available microplate readers. During the establishment, icNT parameters such as antibody concentrations, permeabilization procedures, blocking reagents, infectious doses, and the duration of infection were optimized. Afterwards, a dose-dependent detection of Rabies lyssavirus neutralization was demonstrated using the WHO Standard Rabies Immunoglobulin reference. A panel of 200 sera with known RFFIT titers revealed very good sensitivity and specificity of the icNT. Furthermore, the icNT showed very good intra- and inter-assay precision. By recognizing Rabies lyssavirus-specific antigens, the assay can be applied immediately to automatically quantify the concentration of Rabies lyssavirus nAbs in routine diagnostics or for various basic research questions such as screening for antiviral compounds.<\/jats:p>","DOI":"10.1371\/journal.pntd.0010425","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T18:01:20Z","timestamp":1652205680000},"page":"e0010425","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Establishment and clinical validation of an in-cell-ELISA-based assay for the rapid quantification of Rabies lyssavirus neutralizing antibodies"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6666-4948","authenticated-orcid":true,"given":"Lara","family":"Sch\u00f6ler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2733-3732","authenticated-orcid":true,"given":"Vu Thuy Khanh","family":"Le-Trilling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Dittmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2020-1718","authenticated-orcid":true,"given":"Melanie","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3659-3541","authenticated-orcid":true,"given":"Mirko","family":"Trilling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"pntd.0010425.ref001","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1743-422X-9-50","article-title":"Rabies molecular virology, diagnosis, prevention and treatment.","volume":"9","author":"MZ Yousaf","year":"2012","journal-title":"Virol J"},{"issue":"2","key":"pntd.0010425.ref002","doi-asserted-by":"crossref","first-page":"673","DOI":"10.20506\/rst.37.2.2832","article-title":"Antivirals for human use against rabies and prospects for their future application.","volume":"37","author":"P Koraka","year":"2018","journal-title":"Rev Sci Tech"},{"key":"pntd.0010425.ref003","doi-asserted-by":"crossref","first-page":"17091","DOI":"10.1038\/nrdp.2017.91","article-title":"Rabies.","volume":"3","author":"AR Fooks","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"pntd.0010425.ref004","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrmicro.2018.11","article-title":"The spread and evolution of rabies virus: conquering new frontiers","volume":"16","author":"CR Fisher","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"pntd.0010425.ref005","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.3402\/ehtj.v4i0.7159","article-title":"Bats, emerging infectious diseases, and the rabies paradigm revisited","volume":"4","author":"IV Kuzmin","year":"2011","journal-title":"Emerg Health Threats J"},{"issue":"6","key":"pntd.0010425.ref006","doi-asserted-by":"crossref","first-page":"e1002786","DOI":"10.1371\/journal.ppat.1002786","article-title":"Molecular inferences suggest multiple host shifts of rabies viruses from bats to mesocarnivores in Arizona during 2001\u20132009","volume":"8","author":"IV Kuzmin","year":"2012","journal-title":"PLoS Pathog"},{"issue":"8","key":"pntd.0010425.ref007","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1086\/651267","article-title":"Management and outcomes after multiple corneal and solid organ transplantations from a donor infected with rabies virus","volume":"50","author":"T Maier","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pntd.0010425.ref008","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ijmm.2015.08.013","article-title":"Instructive even after a decade: Complete results of initial virological diagnostics and re-evaluation of molecular data in the German rabies virus \"outbreak\" caused by transplantations","volume":"305","author":"RS Ross","year":"2015","journal-title":"Int J Med Microbiol"},{"issue":"2","key":"pntd.0010425.ref009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/ICO.0b013e3181e4572a","article-title":"Survival after transplantation of corneas from a rabies-infected donor","volume":"30","author":"JM Vetter","year":"2011","journal-title":"Cornea"},{"issue":"11","key":"pntd.0010425.ref010","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa043018","article-title":"Transmission of rabies virus from an organ donor to four transplant recipients","volume":"352","author":"A Srinivasan","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"pntd.0010425.ref011","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1001\/jama.2013.7986","article-title":"Raccoon rabies virus variant transmission through solid organ transplantation","volume":"310","author":"NM Vora","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"pntd.0010425.ref012","first-page":"355","article-title":"Rabies Acquired Through Kidney Transplantation in a Child: A Case Report.","volume":"15","author":"B Saeed","year":"2017","journal-title":"Exp Clin Transplant"},{"issue":"1","key":"pntd.0010425.ref013","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12879-018-3112-y","article-title":"Transmission of rabies through solid organ transplantation: a notable problem in China.","volume":"18","author":"J Zhang","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"3","key":"pntd.0010425.ref014","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s13311-016-0452-4","article-title":"Perspectives in Diagnosis and Treatment of Rabies Viral Encephalitis: Insights from Pathogenesis","volume":"13","author":"A Mahadevan","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"1","key":"pntd.0010425.ref015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/13550280590900427","article-title":"Rabies virus receptors","volume":"11","author":"M. Lafon","year":"2005","journal-title":"J Neurovirol"},{"issue":"2","key":"pntd.0010425.ref016","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.virusres.2005.04.004","article-title":"Replication strategies of rabies virus","volume":"111","author":"S Finke","year":"2005","journal-title":"Virus Res"},{"issue":"1","key":"pntd.0010425.ref017","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrmicro2260","article-title":"The cell biology of rabies virus: using stealth to reach the brain","volume":"8","author":"MJ Schnell","year":"2010","journal-title":"Nat Rev Microbiol"},{"issue":"37","key":"pntd.0010425.ref018","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","article-title":"Rabies vaccines: WHO position paper, April 2018\u2014Recommendations","volume":"36","author":"WHO","year":"2018","journal-title":"Vaccine"},{"issue":"33","key":"pntd.0010425.ref019","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1016\/j.vaccine.2017.12.051","article-title":"The path towards effective antivirals against rabies","volume":"37","author":"D Jochmans","year":"2019","journal-title":"Vaccine"},{"key":"pntd.0010425.ref020","unstructured":"WHO, editor Background paper: Proposed revision of the policy on rabies vaccines and rabies immunoglobulins2017 2017."},{"issue":"2","key":"pntd.0010425.ref021","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1017\/S0025727300019451","article-title":"Rabies in the Talmud","volume":"18","author":"F. Rosner","year":"1974","journal-title":"Med Hist"},{"key":"pntd.0010425.ref022","article-title":"Laboratory techniques in rabies","volume":"1","author":"CE Rupprecht","year":"2018"},{"issue":"1","key":"pntd.0010425.ref023","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/01652176.2017.1343516","article-title":"Rabies\u2014epidemiology, pathogenesis, public health concerns and advances in diagnosis and control: a comprehensive review.","volume":"37","author":"R Singh","year":"2017","journal-title":"Vet Q"},{"issue":"5","key":"pntd.0010425.ref024","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1708-8305.2006.00058.x","article-title":"Awareness of rabies risks and knowledge about preventive measures among experienced German travel health advisors","volume":"13","author":"RS Ross","year":"2006","journal-title":"J Travel Med"},{"issue":"3","key":"pntd.0010425.ref025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/14760584.2015.1011134","article-title":"30 Years of rabies vaccination with Rabipur: a summary of clinical data and global experience","volume":"14","author":"A Giesen","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"37","key":"pntd.0010425.ref026","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","article-title":"Rabies vaccines: WHO position paper, April 2018\u2014Recommendations.","volume":"36","author":"O. World Health","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"pntd.0010425.ref027","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1371\/journal.pntd.0000595","article-title":"Rabies-specific antibodies: measuring surrogates of protection against a fatal disease","volume":"4","author":"SM Moore","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010425.ref028","author":"WHO","year":"2018","journal-title":"WHO expert consultation on rabies: third report: World Health Organization"},{"issue":"5","key":"pntd.0010425.ref029","first-page":"535","article-title":"A rapid reproducible test for determining rabies neutralizing antibody","volume":"48","author":"JS Smith","year":"1973","journal-title":"Bull World Health Organ"},{"issue":"1","key":"pntd.0010425.ref030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0022-1759(97)00212-3","article-title":"Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody","volume":"212","author":"F Cliquet","year":"1998","journal-title":"J Immunol Methods"},{"key":"pntd.0010425.ref031","author":"OIE","year":"2018","journal-title":"Manual of Diagnostic Tests and Vaccines for Terrestrial Animals"},{"issue":"3","key":"pntd.0010425.ref032","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"LJ Reed","year":"1938","journal-title":"American journal of epidemiology"},{"issue":"1","key":"pntd.0010425.ref033","doi-asserted-by":"crossref","first-page":"9893","DOI":"10.1038\/s41598-020-66754-8","article-title":"Preparation and qualification of internal rabies reference standards for use in the rabies rapid fluorescent focus inhibition test","volume":"10","author":"TM Timiryasova","year":"2020","journal-title":"Sci Rep"},{"key":"pntd.0010425.ref034","doi-asserted-by":"crossref","first-page":"112626","DOI":"10.1016\/j.jim.2019.06.017","article-title":"Rapid fluorescent focus inhibition test optimization and validation: Improved detection of neutralizing antibodies to rabies virus","volume":"474","author":"TM Timiryasova","year":"2019","journal-title":"J Immunol Methods"},{"issue":"Pt 6","key":"pntd.0010425.ref035","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1099\/jmm.0.006064-0","article-title":"An evaluation of two commercially available ELISAs and one in-house reference laboratory ELISA for the determination of human anti-rabies virus antibodies","volume":"58","author":"RJ Welch","year":"2009","journal-title":"J Med Microbiol"},{"issue":"5","key":"pntd.0010425.ref036","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ijid.2006.09.013","article-title":"Development and evaluation of a competitive ELISA for estimation of rabies neutralizing antibodies after post-exposure rabies vaccination in humans","volume":"11","author":"K Muhamuda","year":"2007","journal-title":"Int J Infect Dis"},{"issue":"12","key":"pntd.0010425.ref037","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.vaccine.2006.12.012","article-title":"Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people","volume":"25","author":"M Feyssaguet","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"pntd.0010425.ref038","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/104063879901100406","article-title":"Comparison of visual microscopic and computer-automated fluorescence detection of rabies virus neutralizing antibodies","volume":"11","author":"D Peharpre","year":"1999","journal-title":"J Vet Diagn Invest"},{"key":"pntd.0010425.ref039","author":"Food and Drug Administration H","year":"2018","journal-title":"Bioanalytical Method Validation: FederalRegister"},{"issue":"12","key":"pntd.0010425.ref040","doi-asserted-by":"crossref","first-page":"e0007011","DOI":"10.1371\/journal.pntd.0007011","article-title":"A high throughput neutralization test based on GFP expression by recombinant rabies virus","volume":"12","author":"J Burgado","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010425.ref041","doi-asserted-by":"crossref","first-page":"42769","DOI":"10.1038\/srep42769","article-title":"Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system","volume":"7","author":"J Nie","year":"2017","journal-title":"Sci Rep"},{"key":"pntd.0010425.ref042","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.biologicals.2017.02.002","article-title":"G-protein based ELISA as a potency test for rabies vaccines","volume":"46","author":"M Chabaud-Riou","year":"2017","journal-title":"Biologicals"},{"issue":"3","key":"pntd.0010425.ref043","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/aps.2010.209","article-title":"Generation and characterization of the human neutralizing antibody fragment Fab091 against rabies virus","volume":"32","author":"C Li","year":"2011","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"pntd.0010425.ref044","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"SA Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"7","key":"pntd.0010425.ref045","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.celrep.2020.01.070","article-title":"The Human Cytomegalovirus pUL145 Isoforms Act as Viral DDB1-Cullin-Associated Factors to Instruct Host Protein Degradation to Impede Innate Immunity","volume":"30","author":"VTK Le-Trilling","year":"2020","journal-title":"Cell Rep"},{"key":"pntd.0010425.ref046","doi-asserted-by":"crossref","first-page":"104882","DOI":"10.1016\/j.antiviral.2020.104882","article-title":"An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection","volume":"181","author":"C Conzelmann","year":"2020","journal-title":"Antiviral Res"},{"issue":"2673","key":"pntd.0010425.ref047","article-title":"A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds.","volume":"11","author":"L Sch\u00f6ler","year":"2020","journal-title":"Frontiers in Immunology"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0010425","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T17:52:33Z","timestamp":1654105953000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010425"}},"subtitle":[],"editor":[{"given":"Mohamed Gomaa","family":"Kamel","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0010425","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0010425","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]}}}